Kliniken & Institute … Kliniken Chirurgische Klinik… Allgemein-, Viszeral-… Forschung Chirurgische Forschung … AG Molekulare… Publikationen Originalarbeiten 1998-2003

Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer, PH, Knebel-Döberitz M and Debatin K-M (2003). Glucocorticoid co-treatment induces apoptosis resistance towards cancer therapy in carcinomas. Cancer Res., 63, 3112-3120. 

Classen CF, Falk CS, Friesen C, Fulda S, Herr I and Debatin KM (2003). Natural killer resistance of a drug-resistant leukemia cell line, mediated by upregulation of HLA class I expression. Haematol-Hematol, 88, 509-521. 

Krilleke D, Ucur E, Pulte D, Schulze-Osthoff K, Debatin K-M and Herr I (2003). JNK/SAPK signalling is involved in early but not late cellular stress-induced apoptosis. Int. J. Cancer, 107, 520-527. 

Ucur E, Wenger T, Okouoyo S, Mattern J, Schroth A, Debatin K-M and Herr I(2003). Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T Cells. Brit. J. Cancer, 89, 2155-2162. 


Bierbaum H, Baumann S, Herr I, Tuckermann JP, Hess J, Schorpp-Kistner M, Angel P (2003). Early activation and induction of apoptosis is independent of c-Fos. Ann NY Acad Sci, 1010, 225-231.   

Baumann B, Bohnenstengel F, Herr I, Debatin K-M, Proksch P and Wirth T (2002). Rocaglamide derivates are potent inhibitors of NF-κB activation in T cells. J. Biol. Chem, 277, 44791-44800.  

Herr I and Debatin K-M. (2001). Cellular stress response and apoptosis in cancer therapy. Blood, 98, 2603-2614. 
IF 10.555

Herr I, Posovszky C, Boehler T and Debatin K-M (2000). mAb 33 from Transduction Laboratories specifically binds to human CD95-L, Cell Death and Differentiation, 7, 129-130. 

Kolbus A, Herr I, Schreiber M, Debatin K-M, Wagner E and Angel P (2000). c-Jun dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents, Mol. Cell. Biol., 20, 575-582. 

Herr I, Posovszky C, Di Marzio L, Cifone MG, Boehler T and Debatin K-M. (2000). Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-a, Oncogene, 19, 4255-4262. 

Herr I, Krilleke, D and Debatin K-M. (2000). A sensitive, non-radioactive and fast method for detection of JNK/SAPK activity in leukemic T cells, Leukemia, 14, 1859-1860. 

Herr I, Wilhelm D, Boehler T, Angel P and Debatin K-M. (1999). JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-a. Int. J. Cancer 80, 417-424. 

Herr I, Wilhelm D, Meyer, E, Jeremias I, Angel P and Debatin K-M (1999). JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death and Differentiation 6, 130-135. 

Posovszky C, Friesen C, Herr I and Debatin K-M (1999). Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia, 13, 400-409. 

Martin-Villalba A*, Herr I* (*equal contribution), Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T and Debatin K-M (1999). CD95-Ligand (Fas-Ligand/APO-1L) and TRAIL mediate ischemia-induced apoptosis in neurons, J. Neuroscience, 19, 3809-3817. 

Herr I, Martin-Villalba A, Kurz E, Roncaioli P, Schenkel J, Cifone G.M. and Debatin K-M (1999). FK506 inhibits stroke-induced generation of ceramide and apoptosis signaling, Brain-Res., 826, 210-219. 

Bernassola F, Scheuerpflug C, Herr I, Krammer PH, Debatin K-M and Melino G (1999). Induction of apoptosis by IFN[gamma] in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit, Cell Death and Differentiation 6, 652-660. 

Jeremias I, Herr I, Boehler T and Debatin K-M (1998). Trail/APO-2-Ligand induced apoptosis in human T-cells. Eur. J. Immunol. 28, 143-152. 

Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T and Debatin K-M (1998). Sensitivity to TRAIL and doxorubicin induced apoptosis is attenuated by inhibition of NF-κB. Blood 91, 4624-4631.